Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TACR2 | P21452 | 3/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4631235 | 0.92 | KMT2A (0.41) | KMT2ATACR2TACR1 | |
| SCHEMBL6664233 | 0.92 | KMT2A (0.41) | KMT2ATACR2TACR1SLC6A2SLC6A4 | |
| SCHEMBL6662514 | 0.90 | KMT2A (0.39) | KMT2ATACR2TACR1CNR1 | |
| SCHEMBL7501724 | 0.85 | TACR2 (0.51) | KMT2ATACR2TACR1 | |
| SCHEMBL4630864 | 0.85 | TACR2 (0.51) | KMT2ATACR2TACR1 | |
| SCHEMBL6663124 | 0.85 | KMT2A (0.47) | KMT2ATACR2TACR1SLC6A2SLC6A4 | |
| SCHEMBL4630697 | 0.83 | TACR2 (0.50) | TACR2TACR1 | |
| SCHEMBL6199169 | 0.83 | TACR2 (0.39) | KMT2ATACR2SLC6A2SLC6A4CNR1 | |
| SCHEMBL6665548 | 0.83 | KMT2A (0.40) | KMT2ATACR2TACR1CNR1 | |
| SCHEMBL6196499 | 0.81 | CCR5 (0.39) | KMT2ATACR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165528-B1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-09-01 | — | — | EP | disclosed |
| US-6506750-B1 | N-(phenylacetyl)morpholine derivatives useful as NK1 receptor antagonists, a process for the preparation thereof, and pharmaceutical compositions containing them as active principle. | SANOFI-SYNTHELABO (FR) | 2003-01-14 | — | — | US | disclosed |